Just days after Bahija Jallal announced her decision to leave her post at the top of AstraZeneca’s big biologics subsidiary MedImmune and take the helm at Immunocore, the pharma giant is shaking up its R&D leadership and bringing in a controversial new head of oncology R&D.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription